Maintenance therapy with cotrimoxazole for toxoplasmic encephalitis in the era of highly active antiretroviral therapy

Xavier Duval; O Pajot; V Le Moing; P Longuet; J L Ecobichon; F Mentre; C Leport; J L Vilde

doi:10.1097/00002030-200406180-00016

Maintenance therapy with cotrimoxazole for toxoplasmic encephalitis in the era of highly active antiretroviral therapy

AIDS. 2004 Jun 18;18(9):1342-4. doi: 10.1097/00002030-200406180-00016.

Authors

Xavier Duval¹, O Pajot, V Le Moing, P Longuet, J L Ecobichon, F Mentre, C Leport, J L Vilde

Affiliation

¹ Department of Infectious Diseases, Bichat-Claude Bernard Hospital, Paris, France.

PMID: 15362670
DOI: 10.1097/00002030-200406180-00016

Abstract

To reduce the number of daily pills for improving adherence to antiretrovirals, 17 protease inhibitor-treated patients receiving toxoplasmic encephalitis (TE) standard maintenance therapy were instead given cotrimoxazole 960 mg twice daily. After a median follow-up of 31 months, one relapsed after three months, TE relapse incidence = 2.1 cases per 100 patient-years (95% confidence interval, 0.05-11.3). This strategy could be useful for patients awaiting immune reconstitution which allows the interruption of TE maintenance therapy.

MeSH terms

Animals
Anti-HIV Agents / therapeutic use
Anti-Infective Agents / therapeutic use*
Antiretroviral Therapy, Highly Active
CD4 Lymphocyte Count
Female
Follow-Up Studies
HIV Infections / drug therapy
HIV Infections / immunology
HIV Infections / parasitology*
Humans
Male
Recurrence
Toxoplasma*
Toxoplasmosis, Cerebral / prevention & control*
Toxoplasmosis, Cerebral / virology
Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use*
Viral Load

Substances

Anti-HIV Agents
Anti-Infective Agents
Trimethoprim, Sulfamethoxazole Drug Combination